Profile: Novo Nordisk A/S (NVO)
26 Jun 2017
Novo Nordisk A/S, incorporated on November 28, 1931, is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas.
The Company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. The Company also offers products, such as Tresiba (insulin degludec), which is a once-daily-insulin; Xultophy (IDegLira), which is a once-daily single-injection combination of insulin degludec (Tresiba) and liraglutide (Victoza), and Ryzodeg, which is a soluble formulation of insulin degludec and insulin aspart. The Company's Prandin/NovoNorm is an oral antidiabetic drug. The Company's brands, which are in Phase III development include Semaglutide (NN9535)/Type II diabetes; Fast-acting insulin aspart (NN1218)/Type I and II diabetes; Oral semaglutide (NN9924)/Type II diabetes; N9-GP (NN7999)/Haemophilia B; N8-GP (NN7088)/Haemophilia A, and NN8640 Once-weekly human growth hormone/Growth disorder.
As of December 31, 2016, the Company marketed its products in more than 180 countries. The Company's regional structure consists of two main commercial units: North America and International Operations. The Company's North America unit consists of the United States and Canada. The Company's International Operations covers all countries except for North America and is organized in the five regions: Europe; Latin America; Africa, Asia, the Middle East and Oceania (AAMEO); Japan and Korea, and Region China. The Company's production facilities are located at various sites in Denmark, and internationally in the United States, France, China and Brazil. The Company's active pharmaceutical ingredient (API) production sites are located in Denmark and the United States.
Novo Nordisk A/S
Company Web Links
- Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial
- Novo Nordisk says obesity drug helps up to 13.8 pct weight loss in phase 2 trial
- CORRECTED-BRIEF-Novo Nordisk submits EU application for Tresiba label update
- BRIEF-Novo Nordisk says Tresiba showed significant reduction in rates of severe hypoglycaemia compared to insulin glargine
- Novo Nordisk reveals results from real-world study of Tresiba drug